Market News & Trends
Cullinan Oncology Announces Phase 1/2a Interim Data for Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients
Cullinan Oncology, Inc. recently announced additional details pertaining to Cullinan Pearl’s ongoing Phase 1/2a trial of CLN-081 in Non-Small Cell Lung Cancer (NSCLC) patients whose…
Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
Addex Therapeutics recently announced the first patients have been enrolled into a Phase 2 clinical study evaluating JNJ-40411813 (ADX71149) in patients with epilepsy. JNJ-40411813 (ADX71149)…
Mirati Therapeutics & Zai Lab Enter Development & Commercialization Collaboration
Mirati Therapeutics, Inc. and Zai Lab Limited recently announced the companies have entered into a collaboration and license agreement for adagrasib, a small-molecule….
Immutep Enters Into New Collaboration With Merck KGaA
Immutep Limited recently announced a new collaboration and supply agreement with Merck KGaA , Darmstadt, Germany, for a Phase 1/2a clinical trial in patients with….
Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline Into Cancer & Fibrotic Diseases
Corbus Pharmaceuticals Holdings, Inc. recently announced licensing deals for two new monoclonal antibodies (mAbs), CRB-601 and CRB-602, that target integrins to inhibit activation of….
Aptamer Group Collaborates With World-Leading Pharmaceutical Company to Evaluate Optimer Technology
Aptamer Group recently announced that it has signed an agreement with the multinational pharmaceutical and biopharmaceutical company Takeda Pharmaceutical Company Limited…..
Hovione & iBET Announce Strategic Collaboration
Hovione was a founding member of iBET in 1989 and has just re-joined the membership of the Instituto de Biologia Experimental e Tecnológica. In order…
PDS Biotechnology Establishes Partnership With Head & Neck Cancer Alliance
PDS Biotechnology Corporation and the Head and Neck Cancer Alliance (HNCA) recently announced a partnership that seeks to raise awareness of new and developing treatment…
Santhera & ReveraGen Announce Positive & Statistically Highly Significant Topline Results
Santhera Pharmaceuticals and ReveraGen BioPharma, Inc. recently announced positive key results from the VISION-DMD study, demonstrating robust efficacy across multiple efficacy endpoints and favorable safety…
Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum
Verrica Pharmaceuticals Inc. recently announced the US FDA has extended the review period for the New Drug Application (NDA) for VP-102 for the treatment of…
uniQure Announces Positive Recommendation to Advance Phase 1/2 Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
uniQure N.V. recently announced the independent Data Safety Monitoring Board (DSMB) overseeing the Phase 1/2 clinical trial of AMT-130 for the treatment of Huntington’s disease…
Ocugen On Track to Submit EUA Application to US FDA for its COVID-19 Vaccine Candidate
Ocugen, Inc. recently confirmed its plan to submit its Emergency Use Authorization (EUA) application for COVAXIN to the US FDA in June. “Since we have…
EXECUTIVE INTERVIEW - Poseida Therapeutics: Creating the Next Wave of Cell & Gene Therapies With the Capacity to Cure
Eric M. Ostertag, MD, PhD, Chief Executive Officer of Poseida Therapeutics, discusses the company’s innovative approach to develop safer, more effective, accessible and affordable cell and gene therapies for patients.
Microfluidics: An Alternative Method for Developing Nanoparticle Drug Delivery Systems
The encapsulation of drugs within purposely formulated liposome nanoparticles offers the potential for more controlled and sustained release, as well as reducing toxicity and….
Stevanato Group & Corning Incorporated Sign Licensing Agreement to Offer Corning Valor Glass Vials in Presterilized SG EZ-fill Packaging Configuration
Stevanato Group recently announced a licensing agreement with Corning Incorporated to offer a combined solution that will provide biopharmaceutical companies with improved levels of….
Evonik Markets New Enteric-Protected Ready-to-Fill Capsules for Fast, High-Performance Drug Development
Evonik recently launched the EUDRACAP platform of easy-to-handle capsules to help the pharmaceutical industry accelerate speed to market for complex oral drug products in early development stages…..
Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions
Myriad Genetics, Inc. recently announced it has signed a definitive agreement to sell Myriad RBM, Inc. to Q2 Solutions, a leading global clinical trial laboratory services organization….
Ginkgo Bioworks & Biogen Announce Collaboration & License Agreement to Develop Novel Gene Therapy Manufacturing Platform
Ginkgo Bioworks and Biogen recently announced a gene therapy collaboration in which the companies aim to redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors…..
Xalud Therapeutics’ Lead Candidate Achieves Multiple Clinical Milestones in Pathologic Inflammation & Neuroimmunology Therapeutic Areas
Xalud Therapeutics recently announced that the Phase 2b study of XT-150 in patients with moderate-to-severe pain due to osteoarthritis (OA) of the knee has completed…
VBL Therapeutics to Provide Update on OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
VBL Therapeutics recently announced that a poster providing an update on the OVAL Phase 3 registration enabling clinical trial of VB-111 in ovarian cancer will…
